Adverum Biotechnologies (ADVM) Earnings Date, Estimates & Call Transcripts $4.74 +0.04 (+0.85%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Adverum Biotechnologies Latest Earnings SummaryActual EPS (Nov. 4) -$1.30 Missed By -$0.10 Consensus EPS (Nov. 4) -$1.20 Adverum Biotechnologies posted Q3 2024 earnings on November 4, 2024, reporting an EPS of -$1.30, which missed analysts' consensus estimates of -$1.20 by $0.10. Quarterly revenue was reported to be $1 million, above analysts' expectations of $0.50 million. With a trailing EPS of -$5.99, Adverum Biotechnologies' earnings are expected to decrease next year, from ($4.92) to ($5.20) per share. Get Adverum Biotechnologies Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adverum Biotechnologies and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataADVM Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ADVM Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Adverum Biotechnologies Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$1.23-$1.23-$1.23Q2 20241-$1.27-$1.27-$1.27Q3 20241-$1.29-$1.29-$1.29Q4 20241-$1.40-$1.40-$1.40FY 20244($5.19)($5.19)($5.19) Adverum Biotechnologies Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails11/4/2024--$1.20-$1.30 -$0.10-$1.30$0.50M$1.00M8/12/2024Q2 2024-$1.47-$0.89+$0.58-$0.89$0.53M-5/9/2024Q1 2024-$1.28-$1.50 -$0.22-$1.50--3/18/2024Q4 2023-$2.80-$2.30+$0.50-$2.30--11/9/2023Q3 2023-$3.00-$3.30 -$0.30-$0.33--8/10/2023Q2 2023-$3.20-$3.10+$0.10-$0.31-- Get the Latest News and Ratings for ADVM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. 5/11/2023Q1 2023-$3.00-$2.90+$0.10-$0.29-$3.60M3/30/2023Q4 2022-$3.20-$3.30 -$0.10-$0.33-- Adverum Biotechnologies Earnings - Frequently Asked Questions When did Adverum Biotechnologies announce their last quarterly earnings? Adverum Biotechnologies (NASDAQ:ADVM) last announced its quarterly earning data on Monday, November 4, 2024. Learn more on ADVM's earnings history. Did Adverum Biotechnologies beat their earnings estimates last quarter? In the previous quarter, Adverum Biotechnologies (NASDAQ:ADVM) missed the analysts' consensus estimate of ($1.20) by $0.10 with a reported earnings per share (EPS) of ($1.30). Learn more on analysts' earnings estimate vs. ADVM's actual earnings. How much revenue does Adverum Biotechnologies generate each year? Adverum Biotechnologies (NASDAQ:ADVM) has a recorded annual revenue of $1 million. How much profit does Adverum Biotechnologies generate each year? Adverum Biotechnologies (NASDAQ:ADVM) has a recorded net income of -$117.17 million. ADVM has generated -$5.99 earnings per share over the last four quarters. What is Adverum Biotechnologies's EPS forecast for next year? Adverum Biotechnologies's earnings are expected to decrease from ($4.92) per share to ($5.20) per share in the next year. More Earnings Resources from MarketBeat Related Companies Sana Biotechnology Earnings Date Y-mAbs Therapeutics Earnings Date KalVista Pharmaceuticals Earnings Date IGM Biosciences Earnings Date GH Research Earnings Date REGENXBIO Earnings Date Taysha Gene Therapies Earnings Date Alumis Earnings Date Akebia Therapeutics Earnings Date Cryoport Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings 70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today! (Ad)Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.>> You can grab your FREE, laminated copies right here << This page (NASDAQ:ADVM) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
